Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EXEL Exelixis	$51.10 -0.4%	$44.13	$33.76 ▼ $51.63	$12.89B	0.38	2.95 million shs	2.42 million shs
GILD Gilead Sciences	$132.06 -0.7%	$138.14	$97.86 ▼ $157.29	$165.19B	0.31	6.21 million shs	4.53 million shs
NVS Novartis	$149.85 +0.1%	$151.32	$106.71 ▼ $170.46	$285.75B	0.46	1.42 million shs	1.52 million shs
ON onsemi	$118.37 +2.3%	$76.02	$40.62 ▼ $119.10	$45.35B	1.94	14.34 million shs	11.49 million shs
PFE Pfizer	$25.74 -0.8%	$27.01	$22.09 ▼ $28.75	$147.96B	0.35	37.21 million shs	24.05 million shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EXEL Exelixis	-0.37%	+10.58%	+11.43%	+16.35%	+14.45%
GILD Gilead Sciences	-0.74%	-1.49%	-5.97%	-14.79%	+34.23%
NVS Novartis	+0.09%	+3.03%	-2.32%	-8.12%	+42.47%
ON onsemi	+2.30%	+17.51%	+64.40%	+63.92%	+161.88%
PFE Pfizer	-0.83%	-2.78%	-5.12%	-6.65%	+16.95%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EXEL Exelixis	$51.10 -0.4%	$44.13	$33.76 ▼ $51.63	$12.89B	0.38	2.95 million shs	2.42 million shs
GILD Gilead Sciences	$132.06 -0.7%	$138.14	$97.86 ▼ $157.29	$165.19B	0.31	6.21 million shs	4.53 million shs
NVS Novartis	$149.85 +0.1%	$151.32	$106.71 ▼ $170.46	$285.75B	0.46	1.42 million shs	1.52 million shs
ON onsemi	$118.37 +2.3%	$76.02	$40.62 ▼ $119.10	$45.35B	1.94	14.34 million shs	11.49 million shs
PFE Pfizer	$25.74 -0.8%	$27.01	$22.09 ▼ $28.75	$147.96B	0.35	37.21 million shs	24.05 million shs

7 Stocks to Ride The A.I. Megaboom

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EXEL Exelixis	-0.37%	+10.58%	+11.43%	+16.35%	+14.45%
GILD Gilead Sciences	-0.74%	-1.49%	-5.97%	-14.79%	+34.23%
NVS Novartis	+0.09%	+3.03%	-2.32%	-8.12%	+42.47%
ON onsemi	+2.30%	+17.51%	+64.40%	+63.92%	+161.88%
PFE Pfizer	-0.83%	-2.78%	-5.12%	-6.65%	+16.95%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EXEL Exelixis	2.39	Hold	$47.35	-7.33% Downside
GILD Gilead Sciences	2.86	Moderate Buy	$157.04	18.91% Upside
NVS Novartis	2.31	Hold	$141.20	-5.77% Downside
ON onsemi	2.48	Hold	$88.81	-24.97% Downside
PFE Pfizer	2.23	Hold	$28.84	12.05% Upside

Current Analyst Ratings Breakdown

Latest EXEL, GILD, NVS, ON, and PFE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2026	PFE Pfizer	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underperform	$26.00
5/13/2026	ON onsemi	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$95.00 ➝ $100.00
5/11/2026	GILD Gilead Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
5/11/2026	GILD Gilead Sciences	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target		$170.00 ➝ $167.00
5/8/2026	GILD Gilead Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target		$175.00 ➝ $168.00
5/8/2026	GILD Gilead Sciences	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target		$148.00 ➝ $146.00
5/8/2026	GILD Gilead Sciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$155.00 ➝ $157.00
5/8/2026	GILD Gilead Sciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Sector Perform	$123.00 ➝ $122.00
5/7/2026	EXEL Exelixis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$54.00 ➝ $56.00
5/6/2026	PFE Pfizer	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
5/6/2026	EXEL Exelixis	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$51.00 ➝ $55.00

(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EXEL Exelixis	$2.32B	5.54	$3.02 per share	16.94	$7.70 per share	6.64
GILD Gilead Sciences	$29.44B	5.57	$10.39 per share	12.71	$18.87 per share	7.00
NVS Novartis	$54.53B	5.24	$10.75 per share	13.94	$20.40 per share	7.35
ON onsemi	$6.00B	7.74	$4.23 per share	27.98	$18.68 per share	6.34
PFE Pfizer	$62.58B	2.34	$4.36 per share	5.90	$15.86 per share	1.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EXEL Exelixis	$782.57M	$3.01	16.98	13.85	1.08	35.08%	39.89%	30.23%	N/A
GILD Gilead Sciences	$8.51B	$7.34	17.99	13.61	N/A	30.99%	48.19%	18.28%	N/A
NVS Novartis	$13.98B	$6.98	21.47	15.24	2.63	24.87%	38.82%	15.16%	7/21/2026 (Estimated)
ON onsemi	$121M	$1.41	83.95	27.15	1.03	9.46%	12.79%	7.80%	8/3/2026 (Estimated)
PFE Pfizer	$7.77B	$1.31	19.65	9.00	N/A	11.83%	19.44%	8.41%	N/A

Latest EXEL, GILD, NVS, ON, and PFE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2026	Q1 2026	GILD Gilead Sciences	$1.91	$2.03	+$0.12	$1.61	$6.91 billion	$6.96 billion
5/5/2026	Q1 2026	EXEL Exelixis	$0.75	$0.87	+$0.12	$0.8138	$607.51 million	$610.81 million
5/5/2026	Q1 2026	PFE Pfizer	$0.7220	$0.75	+$0.0280	$0.47	$13.84 billion	$14.45 billion
5/4/2026	Q1 2026	ON onsemi	$0.6130	$0.64	+$0.0270	-$0.08	$1.49 billion	$1.51 billion
4/27/2026	Q1 2026	NVS Novartis	$2.11	$1.99	-$0.12	$1.65	$13.44 billion	$13.52 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.28	2.48%	+3.04%	44.69%	10 Years
NVS Novartis	$3.08	2.06%	+5.28%	44.13%	N/A
ON onsemi	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.68%	-13.20%	131.30%	16 Years

Latest EXEL, GILD, NVS, ON, and PFE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2026	GILD Gilead Sciences	quarterly	$0.82	2.45%	6/15/2026	6/15/2026	6/29/2026
4/22/2026	PFE Pfizer	quarterly	$0.43	6.71%	5/8/2026	5/8/2026	6/12/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EXEL Exelixis	N/A	3.26	3.19
GILD Gilead Sciences	0.89	1.97	1.77
NVS Novartis	0.96	0.85	0.65
ON onsemi	0.41	4.87	3.14
PFE Pfizer	0.67	1.25	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EXEL Exelixis	85.27%
GILD Gilead Sciences	83.67%
NVS Novartis	13.12%
ON onsemi	97.70%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
EXEL Exelixis	2.60%
GILD Gilead Sciences	0.30%
NVS Novartis	0.01%
ON onsemi	0.35%
PFE Pfizer	0.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EXEL Exelixis	1,077	251.35 million	244.82 million	Optionable
GILD Gilead Sciences	17,000	1.24 billion	1.24 billion	Optionable
NVS Novartis	75,267	1.91 billion	1.91 billion	Optionable
ON onsemi	22,670	391.90 million	390.53 million	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable

EXEL, GILD, NVS, ON, and PFE Headlines

Recent News About These Companies

Mesirow Financial Investment Management Inc. Cuts Holdings in Pfizer Inc. $PFE

4 minutes ago | marketbeat.com

Pfizer Inc. $PFE Shares Sold by Pinnacle Associates Ltd.

4 minutes ago | marketbeat.com

AustralianSuper Pty Ltd Acquires 671,258 Shares of Pfizer Inc. $PFE

2 hours ago | marketbeat.com

Is Alnylam (ALNY) One of the Best Aggressive Growth Stocks to Buy?

May 14 at 8:17 PM | finance.yahoo.com

Pfizer Just Locked In Its Next 5 Years of Growth -- Here's How

May 14 at 3:16 PM | fool.com

Jim Cramer on Pfizer: “Pfizer Does Not Have Any Earnings Momentum”

May 14 at 3:16 PM | finance.yahoo.com

Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch

May 14 at 3:16 PM | finance.yahoo.com

Pfizer’s Prazosin Site-Transfer Trial Signals Quiet but Important Supply-Chain Progress

May 14 at 1:10 PM | tipranks.com

Pfizer’s New Japan RSV Vaccine Trial Signals Ongoing Expansion for PFE

May 14 at 1:10 PM | tipranks.com

2 Ways to Play the Big Pharma Patent Cliff (PFE)

...

May 14 at 1:00 PM | marketbeat.com

Pfizer Just Locked In Its Next 5 Years of Growth -- Here's How

May 14 at 11:31 AM | fool.com

PFE Stock Declines Post Q1 Beat: Book Profits or Stay Invested?

May 14 at 9:55 AM | zacks.com

Pfizer's Turnaround Is Taking Shape

May 14 at 9:50 AM | seekingalpha.com

World Investment Advisors Buys 40,239 Shares of Pfizer Inc. $PFE

May 14 at 7:22 AM | marketbeat.com

The Zacks Analyst Blog Meta, Pfizer, Salesforce and Smith-Midland

May 14 at 6:21 AM | zacks.com

Rayburn West Financial Services LLC Buys Shares of 47,530 Pfizer Inc. $PFE

May 14 at 6:06 AM | marketbeat.com

Ameritas Advisory Services LLC Buys 90,384 Shares of Pfizer Inc. $PFE

May 14 at 3:04 AM | marketbeat.com

4 stocks to watch on Wednesday: BABA, PFE, TWO, NBIS

May 13 at 11:19 PM | seekingalpha.com

Pfizer granted label expansion for hemophilia therapy Hympavzi in Europe

May 13 at 11:19 PM | seekingalpha.com

Top Analyst Reports for Meta, Pfizer & Salesforce

May 13 at 6:14 PM | finance.yahoo.com

3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally

May 13 at 1:15 PM | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EXEL, GILD, NVS, ON, and PFE Company Descriptions

Exelixis NASDAQ:EXEL

$51.10 -0.19 (-0.37%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$50.91 -0.19 (-0.37%)

As of 04:01 AM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Gilead Sciences NASDAQ:GILD

$132.06 -0.99 (-0.74%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$133.00 +0.94 (+0.71%)

As of 06:08 AM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Novartis NYSE:NVS

$149.85 +0.10 (+0.07%)

Closing price 05/14/2026 03:59 PM Eastern

Extended Trading

$149.47 -0.38 (-0.26%)

As of 05:26 AM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

onsemi NASDAQ:ON

$118.37 +2.66 (+2.30%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$114.16 -4.21 (-3.55%)

As of 06:09 AM Eastern

onsemi is engaged in disruptive innovations and also a supplier of power and analog semiconductors. The firm offers vehicle electrification and safety, sustainable energy grids, industrial automation, and 5G and cloud infrastructure, with a focus on automotive and industrial end-markets. It operates through the following segments: Power Solutions Group, Advanced Solutions Group, and Intelligent Sensing Group. The Power Solutions Group segment offers discrete, module, and semiconductor products that perform multiple application functions, including power switching, power conversion, signal conditioning, circuit protection, signal amplification, and voltage reference functions. The Advanced Solutions Group segment is involved in the designing and developing of analog, mixed-signal, advanced logic, ASSPs and ASICs, Wi-Fi and power solutions for a broad base of end-users in the automotive, consumer, computing, industrial, communications, medical and aerospace/defense markets. The Intelligent Sensing Group segment is focused on the designing and developing of CMOS and CCD image sensors, as well as proximity sensors, image signal processors, single photon detectors, inclu

Pfizer NYSE:PFE

$25.74 -0.22 (-0.85%)

Closing price 05/14/2026 03:59 PM Eastern

Extended Trading

$25.78 +0.04 (+0.14%)

As of 06:08 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EXEL, GILD, NVS, ON, and PFE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EXEL, GILD, NVS, ON, and PFE Earnings

Compare Dividends

Latest EXEL, GILD, NVS, ON, and PFE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EXEL, GILD, NVS, ON, and PFE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EXEL, GILD, NVS, ON, and PFE Company Descriptions

Exelixis NASDAQ:EXEL

Gilead Sciences NASDAQ:GILD

Novartis NYSE:NVS

onsemi NASDAQ:ON

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools